share_log

Lifecome Biochemistry Co.,Ltd.'s (SZSE:002868) 26% Gain Last Week Benefited Both Private Companies Who Own 43% as Well as Insiders

Lifecome Biochemistry Co.,Ltd.'s (SZSE:002868) 26% Gain Last Week Benefited Both Private Companies Who Own 43% as Well as Insiders

Lifecome 生物化學有限公司, Ltd. 's (SZSE: 002868) 上週漲幅26%,使持有43%的私營公司和內部人士受益
Simply Wall St ·  02/23 18:37

Key Insights

關鍵見解

  • Significant control over Lifecome BiochemistryLtd by private companies implies that the general public has more power to influence management and governance-related decisions
  • 51% of the business is held by the top 3 shareholders
  • 33% of Lifecome BiochemistryLtd is held by insiders
  • 私營公司對Lifecome BioChemistryLtd的嚴格控制意味着公衆擁有更大的影響管理和治理相關決策的權力
  • 51% 的業務由前三名股東持有
  • Lifecome BioChemistryLtd33%的股份由內部人士持有

If you want to know who really controls Lifecome Biochemistry Co.,Ltd. (SZSE:002868), then you'll have to look at the makeup of its share registry. We can see that private companies own the lion's share in the company with 43% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

如果你想知道誰真正控制了Lifecome Bijecume Co., Ltd.(深圳證券交易所:002868),那麼你必須看看其股票登記處的構成。我們可以看到,私營公司擁有該公司的大部分股份,所有權爲43%。換句話說,該集團面臨最大的上行潛力(或下行風險)。

While private companies were the group that reaped the most benefits after last week's 26% price gain, insiders also received a 33% cut.

儘管在上週股價上漲26%之後,私營公司是獲得最大收益的群體,但內部人士也獲得了33%的下調。

In the chart below, we zoom in on the different ownership groups of Lifecome BiochemistryLtd.

在下圖中,我們放大了Lifecome BiochemistryLtd的不同所有權群體。

ownership-breakdown
SZSE:002868 Ownership Breakdown February 23rd 2024
SZSE: 002868 所有權明細 2024 年 2 月 23 日

What Does The Lack Of Institutional Ownership Tell Us About Lifecome BiochemistryLtd?

關於Lifecome BiochemistryLtd,缺乏機構所有權告訴我們什麼?

Institutional investors often avoid companies that are too small, too illiquid or too risky for their tastes. But it's unusual to see larger companies without any institutional investors.

機構投資者通常會避開規模太小、流動性太差或風險太大的公司,不符合他們的口味。但是,看到沒有任何機構投資者的大型公司是不尋常的。

There could be various reasons why no institutions own shares in a company. Typically, small, newly listed companies don't attract much attention from fund managers, because it would not be possible for large fund managers to build a meaningful position in the company. On the other hand, it's always possible that professional investors are avoiding a company because they don't think it's the best place for their money. Lifecome BiochemistryLtd might not have the sort of past performance institutions are looking for, or perhaps they simply have not studied the business closely.

沒有機構擁有公司股份的原因可能多種多樣。通常,小型的新上市公司不會引起基金經理的太多關注,因爲大型基金經理不可能在公司中建立有意義的地位。另一方面,專業投資者總是有可能避開一家公司,因爲他們認爲這不是賺錢的最佳去處。Lifecome BioChemistryLtd可能沒有機構想要的那種過去的業績,或者他們可能根本沒有仔細研究該業務。

earnings-and-revenue-growth
SZSE:002868 Earnings and Revenue Growth February 23rd 2024
SZSE: 002868 收益和收入增長 2024 年 2 月 23 日

Hedge funds don't have many shares in Lifecome BiochemistryLtd. The company's largest shareholder is Tan Ping Lai, with ownership of 31%. The second and third largest shareholders are Shangrao Changxin No. 2 Enterprise Management Center (Limited Partnership) and Hangzhou Yirui Investment Partnership Enterprise (Limited Partnership), with an equal amount of shares to their name at 10%. In addition, we found that Tanping Lai, the CEO has 1.0% of the shares allocated to their name.

對沖基金在Lifecome BioChemistryLtd的股份不多。該公司的最大股東是陳平來,所有權爲31%。第二和第三大股東是上饒長信二號企業管理中心(有限合夥)和杭州易瑞投資合夥企業(有限合夥企業),其名下股份數量相等,爲10%。此外,我們發現首席執行官賴坦平擁有1.0%的股份以他們的名義分配。

After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.

在進一步挖掘之後,我們發現前三名股東共同控制了公司一半以上的股份,這意味着他們擁有影響公司決策的巨大權力。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。我們的信息表明,分析師對該股沒有任何報道,因此可能鮮爲人知。

Insider Ownership Of Lifecome BiochemistryLtd

Lifecome BiochemistryLtd 的內部

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

Our information suggests that insiders maintain a significant holding in Lifecome Biochemistry Co.,Ltd.. Insiders own CN¥976m worth of shares in the CN¥3.0b company. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

我們的信息表明,內部人士持有Lifecome生物化學公司的大量股份。,有限公司。內部人士擁有這家30億元人民幣公司價值9.76億元人民幣的股份。我們可以說這表明了與股東的一致性,但值得注意的是,該公司仍然很小;一些內部人士可能已經創立了該公司。你可以點擊這裏查看這些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a 22% stake in Lifecome BiochemistryLtd. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

公衆通常是個人投資者,持有Lifecome BioChemistryLtd22%的股份。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。

Private Company Ownership

私人公司所有權

We can see that Private Companies own 43%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們可以看到,私人公司擁有已發行股份的43%。私營公司可能是關聯方。有時,內部人士通過持有私營公司而不是以個人身份對上市公司感興趣。雖然很難得出任何粗略的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Lifecome BiochemistryLtd , and understanding them should be part of your investment process.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,投資風險的幽靈無處不在。我們已經向Lifecome BioChemistryLtd確定了三個警告信號,了解它們應該是您投資過程的一部分。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論